GLP-1 Agonists Come Out on Top in Cardiovascular Comparison of Newer Diabetes Meds
Diabetes patients adding a newcomer drug to their medications may derive cardiovascular benefits to varying degrees depending on their choice between GLP-1 agonists and SGLT-2 inhibitors, a large observational dataset suggested. Among U.S. veterans already on metformin, sulfonylurea, or insulin treatment and without cardiovascular disease (CVD), the addition of a GLP-1 agonist, instead of a […]